• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Ascelia Pharma - Presentation of Q3 2023

ACE2023-11-09 14:30
HC Andersen Capital
Discuss

Meet and ask questions CEO Magnus Corfitzen from Ascelia Pharma on 9 November at 2.30PM CET.

The topic for this event is the Q3 report and major events during the quarter. It’s been a very busy quarter for Ascelia Pharma with major news flow on the Sparkle study.

Ascelia Pharma is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (Mangoral) and Oncoral – in clinical development. Ascelia Pharma has its global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE).

Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement./Claus Thestrup 3.11 PM 18 October 2023.

Upcoming webcasts

Recent videos

Implantica, Audiocast, Q2'26
2026-08-21 15:00 Implantica
SP Group – Presentation of the quarterly report for Q2 2026
2026-08-21 15:00 SP Group
United Bankers H1’26: Fokus på internationell försäljning
2026-08-21 14:02 United Bankers
Egetis Therapeutics, Audiocast, Q2'26
2026-08-21 14:00 Egetis Therapeutics
HomeMaid Q2'26: Tillväxten rullar på, Företagsstäd kärvar
2026-08-21 13:00 HomeMaid
View all videos